Calliditas Therapeutics Ab (publ) (NASDAQ: CALT)
Some price data may be temporarily unavailable.
Calliditas Therapeutics Ab (publ) Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Calliditas Therapeutics Ab (publ) Company Info
Calliditas Therapeutics AB clinical-stage biopharmaceutical company. It engages in the identification, development, and commercialization of novel treatments in orphan indications. The firm focuses on renal and hepatic diseases with significant unmet medical needs. It offers Nefecon, a proprietary, novel oral formulation of budesonide for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN. The firm product TARPEYO is used to reduce proteinuria in adults with primary immunoglobulin. The company was founded by Mikael Bender and Bengt Åke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.